Corrigendum to "Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction" [Toxicol. Appl. Pharmacol. 241 (2009) 246-252] (DOI:10.1016/j.taap.2009.08.023);Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction

Toxicology and Applied Pharmacology

Volumn 241, Issue 2, 2009, Pages 246-252

  Zawacka Pankau, Joanna ^a,b  

^a UNIVERSITY OF GDA SK   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Ap3A (diadenosine triphosphate); Fhit (fragile histidine triad); Photodynamic treatment; Protoporphyrin IX; Tumor suppressor protein

Indexed keywords

AMINOLEVULINIC ACID; ATR PROTEIN; CHECKPOINT KINASE 1; DIADENOSINE TRIPHOSPHATE; FLUOROURACIL; FRAGILE HISTIDINE TRIAD PROTEIN; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL STRESS; CHROMOSOME 3P; CHROMOSOME TRANSLOCATION; ENZYME SUBSTRATE COMPLEX; GENE INACTIVATION; HUMAN; HYDROLYSIS; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW;

EID: 70350591856     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.013     Document Type: Erratum

References (71)

1. Arlt M.F., Durkin S.G., Ragland R.L., et al. Common fragile sites as targets for chromosome rearrangements. DNA Repair 5 (2006) 1126-1135
2. Barnes L.D., Garrison P.N., Siprashvili Z., et al. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′,5-P1,P3-triphosphate hydrolase. Biochemistry 35 (1996) 11529-11535
3. Bednarz N., Zawacka-Pankau J., and Kowalska A. Protoporphyrin IX induces apoptosis in HeLa cells prior to photodynamic treatment. Pharmacol. Rep. 59 4 (2007) 474-479
4. Bianchi F., Magnifico A., Olgiati C., et al. Fhit proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 103 50 (2006) 18981-18986
5. Boldog F., Gemmill R.M., West J., et al. Drabkin, chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum. Mol. Genet. 6 (1997) 193-203
6. Brenner C., Garrison P., Gilmour J., et al. Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. Nat. Struct. Biol. 3 (1997) 231-238
7. Brenner C., Pace H.C., Garrison P.N., et al. Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng. 10 12 (1997) 1461-1463
8. Carrillo N., and Ceccarelli E.A. Open questions in ferredoxin-NADP + reductase catalytic mechanism. Eur. J. Biochem. 270 (2003) 1900-1915
9. Castano A.P., Demidova T.N., and Hamblin M.R. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 1 (2004) 279-293
10. Cliby W.A., Roberts C.J., Cimprich K.A., et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17 (1998) 159-169
11. Chang K.W., Kao S.Y., Tzeng R.J., et al. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J. Pathol. 196 (2002) 300-306
12. Chaudhuri A.R., Khan I.A., Prasad V., Robinson A.K., Ludueña R.F., and Barnes L.D. The tumor suppressor protein Fhit. A novel interaction with tubulin. J. Biol. Chem. 274 34 (1999) 24378-24382
13. Cortez D., Guntuku S., Qin J., et al. ATR and ATRIP: partners in checkpoint signaling. Science 294 (2001) 1713-1716
14. Dumon K.R., Ishii H., Fong L.Y., et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98 6 (2001) 3346-3351
15. Durkin S.G., Ragland R.L., Arlt M.F., et al. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 246-251
16. Ferens B., Kawiak A., Banecki B., Bielawski K.P., and Zawacka-Pankau J. Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit. Cancer Lett. 280 1 (2009) 101-109
17. 3A) with apoptosis in Fhit-positive HEK293 cells. Cancer Lett. 259 2 (2008) 86-191
18. Glover T.W., and Stein C.K. Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet. 43 (1988) 265a-273a
19. Glover T.W., Coyle-Morris J.F., Li F.P., et al. Translocation t(3;8) (p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lymphocytes. Cancer Genet. Cytogenet. (1988) 69b-73b
20. Golebiowski F., Szulc A., Szutowicz A., and Pawelczyk T. Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch. Biochem. Biophys. 428 (2004) 160-164
21. Hammond E.M., Denko N.C., Dorie M.J., et al. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22 2002 (2002) 1834-1843
22. Hanukoglu I., Rapoport R., Weiner L., and Sklan D. Electron leakage from the mitochondrial NADPH-adrenodoxin reductase-adrenodoxin-P450scc (cholesterol side chain cleavage) system. Arch. Biochem. Biophys. 2 (1993) 489-498
23. Hartl F.U., and Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295 5561 (2002) 1852-1858
24. Huang Y., Garrison P.N., and Barnes L.D. Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5′,5′″-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Biochem. J. 312 (1995) 925-932
25. Huebner K., Garrison P.N., Barnes L.D., et al. The role of the FHIT/FRA3B locus in cancer. Ann. Rev. Genet. 32 (1998) 7-31
26. Hwang P.M., Bunz F., Yu J., et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med. 7 10 (2001) 1111-1117
27. Ishii H., Dumon K.R., Vecchione A., et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res. 61 4 (2001) 1578-1584
28. Ji L., Fang B., Yen N., et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59 (1999) 3333-3339
29. Kato H. Photodynamic therapy for lung cancer - a review of 19 years' experience. J. Photochem. Photobiol. B. 42 (1998) 96-99
30. Kisselev L.L., Justesen J., Wolfson A.D., and Frolova L.Y. Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules?. FEBS Lett. 427 2 (1998) 157-163
31. Lima C.D., D'Amico K.L., Naday I., et al. MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family. Structure 5 6 (1997) 763 a-774 a
32. Lima C.D., Klein M.G., and Hendrickson W.A. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science 278 5336 (1997) 286 b-290 b
33. Liu G., and Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21 (2002) 7195-7204
34. Love D.E.B.W.G. Photodynamic therapy comes of age. I Drugs 3 (2000) 1487-1508
35. Lukusa T., and Fryns J.P. Human chromosome fragility. Biochim. Biophys. Acta 1779 (2008) 3-16
36. Malik Z., and Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br. J. Cancer 56 5 (1987) 589-595
37. Maruyama R., Toyooka S., Toyooka K.O., et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61 (2001) 8659-8663
38. McBride G. Studies expand potential uses of photodynamic therapy. J. Natl. Cancer Inst. 94 (2002) 1740-1742
39. Moan J., and Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23 5 (2007) 3591-3600
40. Murphy G.A., Halliday D., and McLennan A.G. The Fhit tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. Cancer Res. 60 9 (2000) 2342-2344
41. Ohta M., Inoue H., Cotticelli M.G., et al. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
42. Pace H.C., Garrison P.N., Robinson A.K., et al. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5484-5489
43. Pekarsky Y., Zanesi N., Palamarchuk A., Hubner K., and Croce C.M. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol. 3 12 (2002) 748-754
44. Pekarsky Y., Garrison P.N., Palamarchuk A., et al. Fhit is a physiological target of the protein kinase Src. Proc. Natl. Acad. Sci. U.S.A. 101 11 (2004) 3775-3779
45. Pichiorri F., Ishii H., Okumura H., et al. Molecular parameters of genome instability: roles of fragile genes at common fragile sites. J. Cell. Biochem. 104 (2008) 1525-1533
46. Pichiorri F., Palumbo T., Suh S.S., et al. Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol. 4 6 (2008) 815-824
47. Rapoport R., Sklan D., and Hanukoglu I. Electron leakage from the adrenal cortex mitochondrial P450scc and P450c11 systems: NADPH and steroid dependence. Arch. Biochem. Biophys. 317 (1995) 412-416
48. Rassool F.V., McKeithan T.W., Neilly M.E., et al. Preferential integration of marker DNA into the chromosomal fragile site at 3p14.2: a novel approach to cloning fragile sites. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6657-6661
49. Roz L., Gramegna M., Ishii H., Croce C.M., and Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3615-3620
50. Sard L., Accornero P., Tornielli S., et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl. Acad. Sci. U.S.A. 96 15 (1999) 8489-8492
51. Sanchez Y., el-Naggar A., Pathak S., et al. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc. Natl. Acad. Sci. U.S.A. 91 8 (1994) 3383-3387
52. Semba S., and Huebner K. Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression. Mol. Cancer Res. 4 8 (2006) 529-538
53. Schwartz M., Zlotorynski E., and Kerem B. The molecular basis of common and rare fragile sites. Cancer Lett. 232 (2006) 13-26
54. Siprashvili Z., Sozzi G., Barnes L.D., et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 94 25 (1997) 13771-13776
55. Smeets D.F., Scheres J.M., and Hustinx T.W. The most common fragile site in man is 3p14. Hum. Genet. 3 (1986) 215-220
56. Smith D.I., McAvoy S., Zhu Y., et al. Large common fragile site genes and cancer. Semin. Cancer Biol. 17 (2007) 31-41
57. Stringer M., and Moghissi K. Photodiagnosis and fluorescence imaging in clinical practice. Photodiagn. Photodyn. Ther. 1 (2004) 9-12
58. Sutherland G.R., and Richards R.I. The molecular basis of fragile sites in human chromosomes. Curr. Opin. Genet. Dev. 3 (1995) 323-327
59. Tanaka H., Shimada Y., Harada H., et al. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 58 (1998) 3429-3434
60. Tepel M., Jankowski J., Schluter H., Bachmann J., et al. Diadenosine polyphosphates' action on calcium and vessel contraction. Am. J. Hypertens. 10 (1997) 1404-1410
61. Trapasso F., Krakowiak A., Cesari R., J., et al. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. U.S.A. 100 4 (2003) 1592-1597
62. Trapasso F., Pichiorri F., Gaspari M., et al. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J. Biol. Chem. 283 20 (2008) 13736-13744
63. van der Giet M., Jankowski J., Schluter H., Zidek W., and Tepel M. Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. J. Hypertens 16 (1998) 1939-1943
64. Vartanian A., Narovlyansky A., Amchenkova A., Turpaev K., and Kisselev L. Interferons induce accumulation of diadenosine triphosphate (Ap3A) in human cultured cells. FEBS Lett. 381 1-2 (1996) 32-34
65. Vartanian A., Prudovsky I., Suzuki H., Dal Pra I., and Kisselev L. Opposite effects of cell differentiation and apoptosis on Ap3A/Ap4A ratio in human cell cultures. FEBS Lett. (1997) 415 2 (1997) 160-162
66. Virmani A.K., Muller C., Rathi A., et al. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7 (2001) 584-589
67. Werner N.S., Siprashvili Z., Fong L.Y., et al. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res. 60 11 (2000) 2780-2785
68. Zawacka-Pankau J., Kowalska A., Issaeva N., et al. Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy. J. Photochem. Photobiol. B 86 1 (2007) 35a-42a 2007
69. Zawacka-Pankau J., Issaeva N., Hossain S., et al. Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and-independent manner. J. Biol. Chem. 282 4 (2007) 2466b-2472b
70. Zawacka-Pankau J., Krachulec J., Grulkowski I., et al. The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol. Appl. Pharmacol. 232 3 (2008) 487-497
71. Zochbauer-Muller S., Fong K.M., Maitra A., et al. 5′-CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61 (2001) 3581-3585